Key points from article :
Alphabet-owned Isomorphic Labs is ramping up its operations.
UK-registered group was spun out of its sister company DeepMind, Google’s AI unit, in November last year.
Isomorphic is currently in talks with major pharmaceutical companies and is expected to announce a deal in the next few months.
Demis Hassabis is chief executive of both DeepMind and Isomorphic Labs.
"... there was a real opportunity here to apply AI to reimagine drugs discovery,” said Colin Murdoch, chief business officer at DeepMind.
The goal is actually to build an underlying platform - not focused on a specific drug or disease.
Will then partner with pharma to get them out into the clinic.
AI-enabled drug discovery could lead to an additional 50 novel therapies over the next 10 years.
Isomorphic reported a £2.4mn loss for the 11 months to December 2021.
